Patent · US Active

Compositions and methods for inhibiting expression of factor V

US8658782B2 · kind B2 · utility

1Cited by

2References

9Claims

0Family size

Assignee

ALYNYLAM PHARMACEUTICALS, INC. · US

Inventors

Hans-Peter Vornlocher · Bayreuth, DE
John M. Maraganore · Concord, US

Key dates

Filing date	Jan 20, 2011
Grant date	Feb 25, 2014
Priority date	—
Expiry date	Feb 11, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Factor V Leiden mutant gene (Factor V Leiden mutant gene), comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of the Factor V Leiden mutant gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the Factor V Leiden mutant gene using the pharmaceutical composition; and methods for inhibiting the expression of the Factor V Leiden mutant gene in a cell.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.